Late breaking news
Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending experimental rheumatoid arthritis and lupus treatment ocrelizumab after deaths following its use, casting doubt over its future.
Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug’s future.
Swiss pharmaceutical company Roche Group said Monday it has suspended a late-stage trial for a new rheumatoid arthritis and lupus drug after several patients died from infections.
March 8 (Bloomberg) — Roche Holding AG and Biogen Idec Inc. are suspending development of the ocrelizumab treatment for use in arthritis after an independent monitoring board said safety risks outweigh benefits observed in these patients.
Roche suspends rheumatoid arthritis drug study after patient deaths Rheumatoid arthritis - Health - Arthritis - Conditions and Diseases - Musculoskeletal Disorders
BIIB ), along with Roche Holdings, announced Monday the suspension of a testing program for the arthritis drug ocrelizumab due to safety concerns. The Data and Safety Monitoring Board recommended th…
ZURICH (Reuters) - Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending experimental rheumatoid arthritis and lupus treatment ocrelizumab after deaths following i…
Swiss pharmaceutical company Roche Group said Monday it has suspended a late-stage trial for a new rheumatoid arthritis and lupus drug after several patients died from infections. Roche said the drug, ocrelizumab, was developed together with Biogen Idec with… Biogen Idec - Rheumatoid arthritis - Health - Conditions and Diseases - Musculoskeletal Disorders
US biotechnology company Biogen Idec and Swiss drugmaker Roche Holding are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug’s future.
Swiss pharmaceutical company Roche Group said today it has suspended a late-stage trial for a new rheumatoid arthritis and lupus drug after several patients died from infections. Roche said the drug, ocrelizumab, was developed together with Biogen Idec with headquarters in Cambridge, Mass.
gnugent :: Mar.09.2010 :: News :: No Comments »
